Atp1a1 (Ab-23) Antibody

What is ATP1A1 and why is it important in cellular research?

ATP1A1 is the alpha-1 subunit of Na+,K+-ATPase, a transmembrane protein responsible for maintaining electrochemical gradients across the plasma membrane by pumping sodium ions out of cells while pumping potassium ions in . This protein plays crucial roles in numerous cellular processes including signal transduction, cell adhesion, and motility . ATP1A1 has gained significant research interest due to its involvement in pathogen entry mechanisms, as demonstrated with respiratory syncytial virus (RSV) , and its altered expression in various cancers including renal cell carcinoma . When using ATP1A1 (Ab-23) Antibody in research, it's essential to understand that you're targeting a multifunctional protein with tissue-specific expression patterns that may significantly impact experimental interpretation.

What methods are recommended for ATP1A1 detection in tissue samples?

For optimal ATP1A1 detection in tissue samples, immunohistochemistry (IHC) has proven effective with antibody dilutions of approximately 1:400 . The protocol typically involves:

• Cutting tissues into 5-μm thickness sections

• Performing standard hematoxylin-eosin (HE) staining for tissue orientation

• Using ATP1A1 antibody (such as Ab-23) as primary antibody

• Applying appropriate biotinylated secondary antibody (e.g., anti-goat IgG)

• Developing with 3,3′-diaminobenzidine substrate solution

• Counterstaining with hematoxylin

For quantification, a scoring system combining staining intensity (0-3) and percentage of positive cells (0-4) can be implemented, with final scores ranging from 0-12 . This approach allows for semi-quantitative analysis of ATP1A1 expression levels across different tissue samples.

How should ATP1A1 (Ab-23) Antibody be validated for experimental use?

Validation of ATP1A1 (Ab-23) Antibody should follow a multi-step approach:

• Western blotting to confirm specific binding to ATP1A1 protein at the expected molecular weight (approximately 110-kD)

• Positive and negative tissue controls (normal kidney tissue typically shows high ATP1A1 expression and can serve as a positive control)

• siRNA knockdown experiments to confirm specificity (using multiple validated siRNAs targeting ATP1A1)

• Comparison with other detection methods such as mass spectrometry (LC-MS/MS has been successfully used to quantify ATP1A1)

• Testing across multiple cell lines with known ATP1A1 expression profiles

For knockdown validation, researchers should verify both mRNA reduction (by qPCR) and protein reduction (by Western blot), with successful experiments typically showing reduction to below 5% at the mRNA level and approximately 35-39% at the protein level 48 hours post-transfection .

How should experimental controls be designed when studying ATP1A1 function?

When designing experiments to study ATP1A1 function using the Ab-23 antibody, comprehensive controls should include:

• Spatial controls: Include both ATP1A1-high tissues (kidney convoluted tubules) and ATP1A1-low tissues (based on your research context)

• Temporal controls: For studies involving ATP1A1 regulation, examine multiple time points as ATP1A1 clustering has been observed as early as 15 minutes post-infection with RSV, becoming more prominent at 30 minutes and 5 hours

• Knockdown controls: Use multiple validated siRNAs targeting ATP1A1 alongside at least two different scrambled siRNAs as negative controls

• Functional controls: Include cellular viability assessments (e.g., ATP measurements in cell lysates) to ensure observed effects aren't due to cytotoxicity

• Specificity controls: Include comparative studies with proteins that should not be affected by ATP1A1 manipulation (e.g., VSV-GFP infection which was shown to be unaffected by ATP1A1 knockdown)

These control strategies ensure that experimental observations can be confidently attributed to ATP1A1-specific effects rather than technical artifacts or non-specific cellular responses.

What are the most reliable methods for quantifying ATP1A1 expression changes in experimental settings?

For reliable quantification of ATP1A1 expression, a multi-method approach is recommended:

• Protein level quantification:

  • Western blotting with appropriate loading controls

  • Immunofluorescence microscopy with quantitative image analysis

  • ELISA-based quantification

  • Proteomic approaches using spike-in SILAC (Stable Isotope Labeling with Amino acids in Cell culture)

• mRNA level quantification:

  • TaqMan assay for ATP1A1 mRNA levels

  • RT-qPCR with validated primers

• Combined analysis strategies:

  • Calculate relative expression using the ratio of two SILAC ratios (experimental sample/control versus reference sample/control)

  • Correlate protein levels with mRNA expression to identify post-transcriptional regulation mechanisms

In comparative studies, the spike-in SILAC approach has successfully identified a 3.7-fold decrease in ATP1A1 protein in renal cell carcinoma tissues compared to non-cancerous counterparts, while household proteins like β-actin showed similar expression levels (ratio 1.06) .

What cell lines are optimal for studying ATP1A1 function with the Ab-23 antibody?

When selecting cell lines for ATP1A1 studies using the Ab-23 antibody, consider:

• Human respiratory epithelial cells: A549 cells have been successfully used for ATP1A1 studies, particularly in viral entry research

• Renal cell lines: Given ATP1A1's high expression in kidney tissue, renal cell lines are particularly relevant

• Control cell lines: HEK293 cells have been used as controls in quantitative proteomics approaches for ATP1A1 studies

• Validation across multiple cell types: Include both epithelial and non-epithelial cell lines to establish tissue-specific effects

When using these cell lines, carefully monitor baseline ATP1A1 expression levels, as they can vary significantly between cell types. Transfection efficiency for siRNA studies should also be optimized for each cell line, with A549 cells showing successful ATP1A1 knockdown with minimal cytotoxicity over 72 hours .

How can ATP1A1 (Ab-23) Antibody be used to investigate ATP1A1's role in viral entry mechanisms?

The Ab-23 antibody can be employed in sophisticated experimental approaches to investigate ATP1A1's role in viral entry:

• Co-localization studies: Use the Ab-23 antibody alongside viral protein antibodies (e.g., RSV F protein) for immunofluorescence microscopy to visualize temporal and spatial relationships during viral entry

• Time-course analysis: Monitor ATP1A1 redistribution within minutes of viral exposure, focusing on 15-30 minute timepoints when clustering first becomes apparent

• Signaling cascade analysis: Combine ATP1A1 detection with phosphorylation-specific antibodies against c-Src and EGFR to elucidate the ATP1A1-mediated signaling cascade during viral entry

• Inhibitor studies: Use the Ab-23 antibody to monitor ATP1A1 localization and clustering when treating cells with specific ATP1A1-targeting compounds like ouabain (25 nM) or PST2238 (20 μM)

• Macropinocytosis investigation: Combine ATP1A1 staining with macropinosome markers to investigate the relationship between ATP1A1 activation and macropinocytic entry of pathogens

In RSV infection studies, researchers observed ATP1A1 clustering on the plasma membrane as early as 15 minutes post-infection, with clusters becoming more prominent over time. Some clusters partially co-localized with RSV F protein, indicating direct involvement in the viral entry process .

What methodological approaches can resolve discrepancies in ATP1A1 expression data between different detection techniques?

When facing discrepancies in ATP1A1 expression data between different detection techniques, implement these methodological approaches:

• Analytical reconciliation strategies:

  • Compare relative versus absolute quantification methods

  • Assess detection sensitivity limits of each technique (Western blot detection may show ~35% protein reduction while mRNA analysis shows >95% reduction)

  • Examine differences in spatial resolution (whole-cell lysates versus compartment-specific analysis)

• Multi-scale verification approach:

  • mRNA level: Use multiple primer sets targeting different ATP1A1 regions

  • Protein level: Employ multiple antibodies targeting different ATP1A1 epitopes

  • Functional level: Correlate expression data with functional assays (e.g., Na+/K+ transport activity)

• Time-course resolution:

  • Examine temporal dynamics, as ATP1A1 mRNA knockdown (to below 5%) at 48 hours post-transfection may result in only 35-39% protein reduction due to protein stability factors

  • Extended time points may be necessary to observe more complete protein depletion

• Statistical meta-analysis:

  • Pool data from multiple techniques with appropriate normalization

  • Weight results based on technique reliability and sensitivity

These approaches can help researchers resolve seemingly contradictory results and develop a more complete understanding of ATP1A1 expression dynamics.

How can ATP1A1 (Ab-23) Antibody be utilized to investigate the ATP1A1-mediated signaling pathways in cancer progression?

For investigating ATP1A1-mediated signaling in cancer progression, the Ab-23 antibody can be employed in these advanced applications:

• Signalosome complex analysis:

  • Immunoprecipitation with ATP1A1 (Ab-23) Antibody followed by mass spectrometry to identify interacting partners

  • Proximity ligation assays to visualize ATP1A1 interactions with signaling molecules like EGFR and c-Src in intact cells

• Phosphoproteomic integration:

  • Combine ATP1A1 immunoprecipitation with phosphoproteomic analysis to map signaling cascades

  • Focus on Raf/MEK/ERK pathway components which have been directly linked to ATP1A1 function in cancer

• Functional domain analysis:

  • Use the antibody in conjunction with ATP1A1 mutant constructs to determine which protein domains are critical for signaling versus ion transport functions

  • Investigate the caveolae localization of ATP1A1, which has been shown to be important for its signaling capacity

• ROS production correlation:

  • Combine ATP1A1 expression analysis with ROS detection methods to investigate the relationship between ATP1A1 levels and oxidative stress in cancer progression

Research has demonstrated that exogenous upregulation of ATP1A1 inhibits renal cancer cell proliferation and migration by increasing ROS production and suppressing the Raf/MEK/ERK signaling pathway, ultimately inducing apoptosis .

What are common technical challenges when using ATP1A1 (Ab-23) Antibody in immunofluorescence microscopy?

When using ATP1A1 (Ab-23) Antibody for immunofluorescence microscopy, researchers may encounter these challenges and solutions:

• Membrane protein detection issues:

  • Challenge: Poor membrane protein preservation during fixation

  • Solution: Use mild fixation protocols (2-4% paraformaldehyde for shorter durations) and avoid methanol fixation which can disrupt membrane protein epitopes

• Clustering visualization difficulties:

  • Challenge: Distinguishing authentic ATP1A1 clusters from artifacts

  • Solution: Implement super-resolution microscopy techniques and include time-course controls to monitor cluster formation (e.g., from 15 minutes to 5 hours post-treatment)

• Co-localization interpretation:

  • Challenge: Partial co-localization with interacting proteins can be difficult to quantify

  • Solution: Use appropriate co-localization coefficients (Pearson's, Manders') and include controls for random co-localization

• Signal-to-noise optimization:

  • Challenge: High background in ATP1A1-rich tissues like kidney

  • Solution: Optimize blocking (use 5% BSA or serum matching secondary antibody host) and implement longer washing steps

• Determining antibody specificity:

  • Challenge: Confirming signal authenticity in immunofluorescence

  • Solution: Include ATP1A1 knockdown controls and competitive binding assays with known ATP1A1 peptides

Researchers studying RSV infection have successfully visualized ATP1A1 clustering on plasma membranes using optimized immunofluorescence protocols that capture early events in protein redistribution .

How can researchers address variability in ATP1A1 detection across different tissue types?

To address variability in ATP1A1 detection across tissue types:

• Tissue-specific optimization strategies:

  • Adjust antibody concentration based on known ATP1A1 expression levels (lower concentrations for high-expression tissues like kidney)

  • Modify antigen retrieval methods for different tissue fixation characteristics

  • Customize blocking protocols to account for tissue-specific non-specific binding

• Internal normalization approaches:

  • Use tissue-specific housekeeping proteins for normalization

  • Implement spike-in standards appropriate for each tissue type

  • Consider relative quantification rather than absolute values when comparing across tissues

• Reference range establishment:

  • Develop tissue-specific scoring systems for semi-quantitative analysis

  • Create a reference atlas of expected ATP1A1 staining patterns in different tissues

  • Establish normal expression ranges for each tissue type based on multiple samples

• Technical standardization:

  • Process different tissue types simultaneously under identical conditions

  • Use automated staining platforms to minimize technical variation

  • Implement digital image analysis with tissue-specific algorithms

These strategies can help researchers account for the intrinsic variability in ATP1A1 expression, which ranges from very high in kidney convoluted tubules to significantly lower in certain cancer tissues .

What methodological approaches can distinguish between total and functional ATP1A1 populations?

Distinguishing between total and functional ATP1A1 populations requires sophisticated methodological approaches:

• Activity-based detection methods:

  • Combine ATP1A1 (Ab-23) antibody staining with ouabain-sensitive ATPase activity assays

  • Use fluorescent ouabain derivatives to specifically label functional Na+/K+-ATPase

• Conformation-specific antibody applications:

  • Pair Ab-23 antibody (for total ATP1A1) with conformation-specific antibodies that recognize only active or inactive forms

  • Compare staining patterns under conditions that modify ATP1A1 activity (e.g., ionic concentration changes)

• Cell surface biotinylation:

  • Use cell-impermeable biotinylation reagents to specifically label surface-exposed ATP1A1

  • Compare total ATP1A1 (from whole cell lysates) with functional surface pools

• Phosphorylation state analysis:

  • Combine ATP1A1 detection with phospho-specific antibodies targeting known regulatory sites

  • Correlate phosphorylation states with functional measures of Na+/K+-ATPase activity

• Microdomain localization assessment:

  • Analyze ATP1A1 distribution in caveolae and non-caveolae membrane fractions

  • Use cholesterol depletion to disrupt caveolae and measure effects on ATP1A1 signaling capacity

These approaches provide researchers with tools to distinguish between the total population of ATP1A1 and the functionally active subpopulation, which is critical for interpreting experimental results in signaling and transport studies.

How should researchers interpret discrepancies between ATP1A1 mRNA and protein levels in experimental systems?

When interpreting discrepancies between ATP1A1 mRNA and protein levels:

• Post-transcriptional regulation analysis:

  • Investigate microRNA-mediated regulation of ATP1A1 mRNA

  • Examine RNA-binding proteins that may affect ATP1A1 mRNA stability

  • Consider alternative splicing of ATP1A1 that may affect antibody recognition

• Protein stability considerations:

  • Assess ATP1A1 protein half-life in your experimental system

  • Note that significant differences in knockdown efficiency have been observed between mRNA (>95% reduction) and protein levels (only 35-39% reduction) at 48 hours post-transfection, suggesting substantial protein stability

  • Examine proteasomal and lysosomal degradation pathways for ATP1A1

• Temporal dynamics interpretation:

  • Implement detailed time-course experiments to capture the lag between mRNA changes and protein level alterations

  • Consider that ATP1A1 protein levels may not show further reduction beyond 48-72 hours despite continued low mRNA levels

• Translational efficiency evaluation:

  • Investigate factors affecting ATP1A1 mRNA translation efficiency

  • Consider polysome profiling to assess translational status of ATP1A1 mRNA

What considerations are important when analyzing ATP1A1's dual role in ion transport versus signal transduction?

When analyzing ATP1A1's dual role in ion transport versus signal transduction:

• Functional domain separation strategies:

  • Distinguish between ATP1A1's ion transport function and its signaling scaffolding role

  • Consider that ouabain and PST2238 bind to the extracellular domain of ATP1A1 and affect both ion transport and signaling functions

• Signaling-specific analysis approaches:

  • Focus on ATP1A1's interactions with signaling proteins like c-Src and EGFR

  • Analyze ATP1A1-dependent activation of the Raf/MEK/ERK pathway, which has been implicated in both viral entry mechanisms and cancer progression

• Transport function isolation methods:

  • Use electrophysiological techniques to specifically measure ion transport activity

  • Employ ion-selective fluorescent indicators to monitor Na+ and K+ flux

• Microenvironment context interpretation:

  • Consider that ATP1A1 localization in caveolae may facilitate its signaling functions

  • Analyze how cholesterol content affects the balance between transport and signaling functions

• Comparative inhibitor analysis:

  • Different concentrations of inhibitors like ouabain (25 nM) may preferentially affect signaling versus transport functions

  • Compare effects of various ATP1A1-targeting compounds on signaling versus ion homeostasis

Understanding this functional duality is critical for correctly interpreting experimental results, particularly in disease contexts where ATP1A1 may contribute to pathogenesis through signaling mechanisms rather than ion transport dysfunction.

How can researchers differentiate between direct and indirect effects of ATP1A1 manipulation in complex biological systems?

To differentiate between direct and indirect effects of ATP1A1 manipulation:

• Temporal resolution strategies:

  • Implement detailed time-course experiments to establish cause-effect relationships

  • Focus on early events (15-30 minutes) following ATP1A1 manipulation to identify direct effects

• Pathway inhibitor combination approaches:

  • Systematically block downstream pathways to isolate ATP1A1-specific effects

  • Use inhibitors of c-Src, EGFR, and MEK/ERK to determine which effects are mediated through these signaling pathways

• Rescue experiment design:

  • Perform genetic rescue with wild-type ATP1A1 versus function-specific mutants

  • Create ATP1A1 variants that selectively restore either ion transport or signaling functions

• Proximity-based interaction analysis:

  • Employ proximity ligation assays or FRET-based approaches to confirm direct protein-protein interactions

  • Distinguish between physical complex formation and functional pathway activation

• Multi-omics data integration:

  • Combine proteomic, transcriptomic, and metabolomic data to construct network models

  • Use computational approaches to distinguish direct ATP1A1 interactors from downstream effectors

These methodological approaches enable researchers to build more accurate models of ATP1A1 function in complex biological contexts, such as viral infection mechanisms or cancer progression , where multiple simultaneous processes may obscure direct causal relationships.